WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H465246
CAS#: unknown
Description: AtuFECT01 is a cationic lipid for RNA and vaccine delivery.
Hodoodo Cat#: H465246
Name: AtuFECT01
CAS#: unknown
Chemical Formula: C45H94Cl3N7O2
Exact Mass: 869.65
Molecular Weight: 871.644
Elemental Analysis: C, 62.01; H, 10.87; Cl, 12.20; N, 11.25; O, 3.67
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: AtuFECT01; Atu FECT01; Atu-FECT01;
IUPAC/Chemical Name: (S)-5-((amino(iminio)methyl)amino)-1-(((S)-2-ammonio-3-(((Z)-octadec-9-en-1-yl)(octadecyl)amino)-3-oxopropyl)amino)-1-oxopentan-2-aminium chloride
InChi Key: BODCXNSAWWEBPF-PTUOKWFHSA-N
InChi Code: InChI=1S/C45H91N7O2.3ClH/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38-52(44(54)42(47)40-51-43(53)41(46)36-35-37-50-45(48)49)39-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;;;/h17,19,41-42H,3-16,18,20-40,46-47H2,1-2H3,(H,51,53)(H4,48,49,50);3*1H/b19-17-;;;/t41-,42-;;;/m0.../s1
SMILES Code: NC(NCCC[C@H]([NH3+])C(NC[C@H]([NH3+])C(N(CCCCCCCCCCCCCCCCCC)CCCCCCCC/C=C\CCCCCCCC)=O)=O)=[NH2+].[Cl-].[Cl-].[Cl-]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 871.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Charbe NB, Amnerkar ND, Ramesh B, Tambuwala MM, Bakshi HA, Aljabali AAA, Khadse SC, Satheeshkumar R, Satija S, Metha M, Chellappan DK, Shrivastava G, Gupta G, Negi P, Dua K, Zacconi FC. Small interfering RNA for cancer treatment: overcoming hurdles in delivery. Acta Pharm Sin B. 2020 Nov;10(11):2075-2109. doi: 10.1016/j.apsb.2020.10.005. Epub 2020 Oct 13. PMID: 33304780; PMCID: PMC7714980.
2: Williamson B, Soars AC, Owen A, White P, Riley RJ, Soars MG. Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA. Xenobiotica. 2013 Oct;43(10):920-31. doi: 10.3109/00498254.2013.776194. Epub 2013 Mar 6. PMID: 23461378.
